Early placebo-controlled rituximab trial
Fluge Ø et al. · 2011 · PLOS ONE
Indexed 2026-11-12.
Reported findings and study design
Reported findings
Two IV rituximab infusions of 500 mg/m² or saline two weeks apart. The prespecified primary endpoint was self-reported fatigue at three months.
Dose, route and schedule
Two IV rituximab infusions of 500 mg/m² or saline two weeks apart. The prespecified primary endpoint was self-reported fatigue at three months.
Protocol source ↗ · Original article abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Three-month primary endpoint | No significant difference in fatigue at three months. | |
| Response over follow-up | 10/15 with rituximab versus 2/15 with placebo met the reported major or moderate response definition. |
The later response signal was secondary and came from a small trial. A larger randomized trial did not reproduce it.
Source for these results ↗ · Reviewed 2026-11-12
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- The later response signal was secondary and came from a small trial. A larger randomized trial did not reproduce it.
Source access
Two IV rituximab infusions of 500 mg/m² or saline two weeks apart. The prespecified primary endpoint was self-reported fatigue at three months.
Source reviewed 2026-11-12.
Citation and original source
Original source: Fluge Ø et al.. Early placebo-controlled rituximab trial PLOS ONE 2011.
Molekul research summary: https://molekul.io/research/rituximab-early-2011. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry